KOSDAQRetail & Consumer014100

Medience

₩1,607▼ 5.30%2026-11-18 close
Market Cap
₩19B
Turnover
₩12,577,620
Volume
7.8K
Shares out.
11.8M
PER
—
PBR
0.3×
EPS
-₩158
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales flat and losses narrowing, quarterly results mixed

Medience's annual sales have declined since 2023, and its quarterly operating results have swung between profit and loss in 2026, so the loss at the controlling-shareholder level has not yet been resolved.

  1. 1

    Annual sales fell from KRW 71.4 billion in 2022 to KRW 48.8 billion in 2025, with three consecutive years of decline from 2023 through 2025.

  2. 2

    The operating loss narrowed to KRW 1.1 billion in 2025, and the Q3 2026 operating loss of KRW 261 million was smaller than a year earlier.

  3. 3

    Net loss attributable to controlling shareholders was KRW 2.98 billion in Q2 2026 and KRW 1.25 billion in Q3 2026, and the last four quarters total KRW 1.79 billion.

  4. 4

    Debt-to-equity rose from 43.7% in 2022 to 60.3% in 2025, while operating cash flow was KRW 0.1 million in 2025, effectively no cash generation.

  5. 5

    Overseas channel expansion continues, including a reported 11-year run at the top of China's Singles' Day ranking and a 2026 listing at a major Kazakh pharmacy chain.

02

Business structure

Medience is a baby-products company listed on KOSDAQ in 1995, centered on the B&B skincare line, the Dr. Ato brand for sensitive skin, and the Upis feeding and infant-care line. According to Butler's compilation of Q2 2026 sales, skincare and products account for 82% of revenue and the apparel business for 18%.

The company emphasizes product safety, supported by naturally derived ingredients and a number of patented technologies, and targets parents in Korea and overseas. Export destinations grew to 19 countries in 2024, adding Japan, Russia, India and the UAE on top of China and the United States.

In a June 2024 announcement the company cited a 35% year-on-year sales increase, a figure it reported itself. A company information page lists B&B as having ranked first in China's Singles' Day for 11 consecutive years. In June 2026 Dr. Ato was listed at a large pharmacy chain in Kazakhstan.

The competitive field includes domestic baby-care brands as well as regional brands in China and Southeast Asia, and the company positions its safety and ingredient standards as differentiators.

At CBME China 2026 in Shanghai in July 2026, the company held talks with buyers from China, Southeast Asia, the Middle East and Europe, which it described as groundwork for new channels. Public figures on sales by country and channel are limited, so the business is best read by brand and region.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.9B-₩1.7B−14.4%
2025Q4₩10.7B₩67,648,0820.6%
2026Q1₩11.9B₩1.3B10.7%
2026Q2₩14B-₩1.3B−9.2%
2026Q3₩12.3B-₩300M−2.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩71.4B₩1.6B-₩11.7B2.3%−14.5%43.7%
2023₩66B-₩1.3B₩7B−2.0%8.0%39.8%
2024₩49B-₩8.8B-₩13.8B−18.0%−18.7%53.0%
2025₩48.8B-₩1.1B-₩6B−2.3%−8.8%60.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales fell from KRW 71.4 billion in 2022 to KRW 66 billion in 2023 (down 7.6% year on year) and KRW 49 billion in 2024 (down 25.8%), and stood at KRW 48.8 billion in 2025 (down 0.4%).

Sales declined for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest in the 2022 to 2025 period. After the steep 2024 drop, the 2025 decline of 0.4% shows the pace of decline slowed.

Operating income moved from KRW 1.61 billion in 2022 to an operating loss of KRW 1.29 billion in 2023, and the loss widened to KRW 8.82 billion in 2024 before narrowing to KRW 1.1 billion in 2025. The operating margin went from 2.3% in 2022 to -2.0% in 2023 and -18.0% in 2024, then -2.3% in 2025.

The sharp margin drop in 2024 reads as a result of costs not adjusting as sales fell by a large amount. Net income attributable to controlling shareholders turned to a profit of KRW 6.99 billion in 2023, yet a profit in a year with an operating loss suggests non-operating items played a role.

The controlling-shareholder net loss returned at KRW 13.8 billion in 2024 and narrowed to KRW 6.02 billion in 2025. Operating cash flow fell from KRW 2.22 billion in 2022 to KRW 369 million in 2023, then to a negative KRW 2.2 billion in 2024 and KRW 0.1 million in 2025, leaving effectively no cash generation in 2025.

The debt-to-equity ratio rose from 43.7% in 2022 to 60.3% in 2025. At the end of 2025, total equity was KRW 68.2 billion, all attributable to controlling shareholders, against total liabilities of KRW 41.1 billion.

On a quarterly basis, the operating loss of KRW 1.73 billion in Q3 2025 became an operating profit of KRW 67.65 million in Q4 2025, and Q1 2026 operating profit of KRW 1.28 billion rose 1,784.9% from the prior quarter.

Q2 2026 sales of KRW 14 billion were the highest of the last five quarters, yet the company posted an operating loss of KRW 1.29 billion. Q3 2026 sales of KRW 12.3 billion fell 12.1% from the prior quarter but rose 3.3% from a year earlier, and the operating loss narrowed to KRW 261 million.

The controlling-shareholder net loss of KRW 1.25 billion in the same quarter was wider than a year earlier. Whether one-off items drove these quarterly swings is a point to confirm in the notes to the periodic reports.

05

Industry analysis

The baby-products market in which Medience operates faces a structural headwind from declining births. The company describes itself as pursuing business diversification in response to changes in the market environment, including the low birthrate.

In Korea, B&B is presented as a leading brand in baby daily goods, and a company information page lists the brand as ranked first for seven consecutive years in the baby-products category of the Korea Management Association Consultants' most respected companies survey.

China is the company's core overseas market, and a Singles' Day top ranking and a Chinese NMPA hygiene permit for children's cosmetics are cited as support for its local position. One media report said industry observers expect Medience to accelerate its push into the Chinese market.

Coverage of CBME 2026 described growing interest in low-irritation, high-function products and ingredient safety in global infant skincare. The company's naturally derived ingredients and safety standards align with that trend.

Whether the trend converts into faster sales growth should be tracked through future sales figures.

Against larger consumer-goods and retail companies, annual sales of KRW 48.8 billion place Medience on the smaller side, so its position in the sector depends on how quickly overseas channels grow relative to the effect of falling domestic births.

06

Outlook

After CBME China 2026, the company said it would accelerate expansion of its local distribution network and development of customized new products.

The B&B sherbet cream, foam cleanser and lip care cream, along with the China-only fragrance booster and soap shown at the same fair, are product lines whose sales will be visible in future results. Dr.

Ato's SimplyBreed nasal tissue and hand-to-mouth tissue were presented as planned launches as of July 2026, and the company said it was assessing the possibility of a global release. In April 2026 the company signed an MOU with Suncheon City to build a base for business expansion.

With the listing at a large pharmacy chain in Kazakhstan adding an overseas sales outlet, the local sales contribution after the listing is the next point to check.

At the annual general meeting on March 27, 2026, the financial statements for the 47th term (2025), including the consolidated statements, were approved, and the re-election of inside director Park Su-chan was passed. The approval of the director compensation limit was left pending and lapsed automatically.

The 2026 full-year result will depend on how the Q1 profit and Q2 loss combine. Q4 2026 results have not yet been filed in a periodic report, so the direction of full-year operating and controlling-shareholder net results will be settled in the 2026 annual report.

Whether new overseas listings and products change the sales mix should be tracked through the segment sales trend in that report.

07

Valuation

PER
—
PBR
0.3×
ROE
-2.7%
EPS
-₩158
BPS
₩5,833
Dividend per share
₩0

The price-to-book ratio sits well below 1x, so the market values the company well under its book net assets. Market capitalization is below the book value of total equity. Because the last four quarters show a controlling-shareholder net loss, earnings-based multiples are not calculated.

Given that results have moved between losses and profits in recent years, whether earnings-based multiples can meaningfully recover depends on whether controlling-shareholder net income turns positive in consecutive periods. The dividend yield is effectively near zero, so shareholder payouts are minimal.

A news report on November 11, 2026 described foreign investors as net buyers for five consecutive days on a preliminary basis, but short-term flow data are volatile and are viewed separately from business value.

The gap between the market value and the size of net assets is tied to weak earnings power and cash generation. A fuller valuation read is more accurate once the controlling-shareholder earnings and operating cash flow in the 2026 annual report are confirmed.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrowing quarterly operating losses

The Q3 2026 operating loss narrowed to KRW 261 million from a larger loss a year earlier, and Q4 2025 posted an operating profit of KRW 67.65 million. Q1 2026 operating profit of KRW 1.28 billion rose 1,784.9% from the prior quarter. Even with quarter-to-quarter swings, the recent narrowing of operating losses is the main bullish data point.

Expanding overseas channels

A company information page lists B&B as having ranked first in China's Singles' Day for 11 consecutive years. Dr. Ato was listed at a large pharmacy chain in Kazakhstan in June 2026. The company said it held talks with buyers from China, Southeast Asia, the Middle East and Europe at CBME China in July 2026. Export destinations reached 19 countries in 2024.

Equity base and no capital impairment

At the end of 2025, total equity of KRW 68.2 billion exceeded total liabilities of KRW 41.1 billion, so the company is not in capital impairment. The price-to-book ratio sits well below 1x. With a sizable equity base, the balance sheet retains some buffer even during loss-making periods.

09

Bear factors

Three straight years of sales decline

Annual sales declined for three consecutive years from 2023 through 2025, and 2025 sales of KRW 48.8 billion were well below the KRW 71.4 billion of 2022. Q3 2026 sales rose 3.3% year on year, but quarterly sales are volatile, falling 12.1% from KRW 14 billion in Q2 2026 to KRW 12.3 billion. Whether the recovery reverses the annual trend will be visible in the 2026 annual report.

Continued losses at the controlling-shareholder level

Net loss attributable to controlling shareholders was KRW 2.98 billion in Q2 2026 and KRW 1.25 billion in Q3 2026, with the Q3 loss wider than a year earlier. Cumulated over four quarters, the net loss has not yet been offset by profits. Operating losses narrowed, but the controlling-shareholder result has not yet stabilized in profit.

Weak cash generation and rising debt

The debt-to-equity ratio rose from 43.7% in 2022 to 60.3% in 2025. Operating cash flow was negative KRW 2.2 billion in 2024 and KRW 0.1 million in 2025. With weak cash generation, the core business has limited capacity to cover its losses from its own cash.

10

Risk factors

Dependence on China

China is central to overseas growth, and sales there can swing with online event results and channel competition. A Singles' Day ranking reflects one event and does not guarantee annual sales. Changes in local regulation or cosmetics permit requirements could also affect sales conditions.

Low birthrate and domestic demand

The company describes itself as pursuing diversification in response to changes in the market environment, including the low birthrate. Falling domestic births reduce the base of demand for baby products over the long term. Any contribution from diversification to sales may take time to appear.

Financial structure and governance

The debt-to-equity ratio reached 60.3%, and operating cash flow was only KRW 0.1 million in 2025. At the March 2026 general meeting, the director compensation limit was left pending and lapsed automatically. The company's past trading suspension after a qualified audit opinion is also recorded as a risk factor.

11

What to watch next

  1. End of March 2027

    Filing of the 2026 annual report. Full-year 2026 sales, operating results, controlling-shareholder net results and operating cash flow are settled here, showing whether Q4 changed the annual loss picture.

  2. Around the 2027 annual general meeting

    Whether the director compensation limit item returns to the agenda after lapsing at the 2026 meeting, and whether there are changes to the board or the management structure.

  3. After December 2026 (date not set)

    Whether the Dr. Ato nasal and hand-to-mouth tissues launch, and how new overseas listings such as Kazakhstan contribute to sales. The key question is whether overseas expansion offsets the domestic sales decline.

12

Overall view

Medience's annual sales have declined for three consecutive years since 2023, and the operating loss narrowed to KRW 1.1 billion in 2025, yet the controlling-shareholder net loss of KRW 6.02 billion remained.

Quarterly results in 2026 were mixed, with a Q1 operating profit of KRW 1.28 billion, a Q2 operating loss of KRW 1.29 billion and a Q3 operating loss of KRW 261 million. The last four quarters total a controlling-shareholder net loss of KRW 1.79 billion.

Bullish points include the narrowing operating loss, overseas channel gains such as the Singles' Day ranking and the Kazakh listing, and an equity base that exceeds total liabilities.

Bearish points include three years of sales decline, a continuing controlling-shareholder loss, a debt-to-equity ratio that rose to 60.3%, and operating cash flow of KRW 0.1 million in 2025. On valuation, the price-to-book ratio sits well below 1x, but earnings-based multiples are not calculated.

The items to confirm are controlling-shareholder earnings and operating cash flow in the 2026 annual report, and whether new overseas listings and products change the sales trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. topdaily.kr
  2. hankyung.com
  3. butler.works
  4. moneypie.net
  5. comp.fnguide.com
  6. app.rndcircle.io
  7. hankyung.com
  8. saramin.co.kr
  9. jobkorea.co.kr
  10. saramin.co.kr
  11. news.nate.com
  12. biz.heraldcorp.com
  13. m.news.nate.com
  14. prnewswire.com
  15. denews.co.kr
  16. m.news.nate.com
  17. supple.kr
  18. newspim.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis